Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Thejeel B, Geannette CS, Roytman M, Pisapia DJ, Chazen JL, Jawetz ST. Patterns of Intrathecal Ossification in Arachnoiditis Ossificans: A Retrospective Case Series. AJNR Am J Neuroradiol. 2023;44(2):228-234.

Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, et al. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol. 2023;83(6):486-494.

Callum J, Bégin P, Jamula E, Liu Y, Kron AT, Auclair M-, et al. Lessons learned from the CONCOR-1 trial. Transfus Med. 2023;33(1):21-25.

Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, et al. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023;7:e2200334.

Baillargeon D, Greenblatt M, Côté M, Nadeau M, Couture C-, Hould F-, et al. Prevalence of Helicobacter pylori Infection in Bariatric Surgery Patients. Obes Surg. 2023;33(7):2132-2138.

Zhang T, Li S, Tan YA, Na JH, Chen Z, Damle P, et al. Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis. bioRxiv. 2023.

Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, et al. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Lancet Haematol. 2023;10(8):e624-e632.

Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis GB, Mandell M, et al. Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. NPJ Precis Oncol. 2023;7(1):9.

2022

Fowler FC, Chen B-, Zolnerowich N, Wu W, Pavani R, Paiano J, et al. DNA-PK promotes DNA end resection at DNA double strand breaks in G0 cells. Elife. 2022;11.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Front Endocrinol (Lausanne). 2022;13:1006101.